Kintara Therapeutics and TuHURA Biosciences Enter into Definitive Merger Agreement April 3, 2024 • 7:00 AM EDT
Kintara Therapeutics Announces Expansion of REM-001 Clinical Study to Include Patients on Pembrolizumab March 27, 2024 • 9:00 AM EDT
Kintara Therapeutics Announces Fiscal 2024 Second Quarter Financial Results and Provides Corporate Update February 14, 2024 • 4:07 PM EST
Kintara Therapeutics Announces Initiation of REM-001 Clinical Trial for the Treatment of Cutaneous Metastatic Breast Cancer February 12, 2024 • 9:00 AM EST
Kintara Therapeutics Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement December 5, 2023 • 9:00 AM EST
Kintara Therapeutics Announces Fiscal 2024 First Quarter Financial Results and Provides Corporate Update November 13, 2023 • 4:10 PM EST
Kintara Therapeutics Announces Preliminary Topline Results From GBM AGILE Study October 31, 2023 • 8:00 AM EDT
Kintara Therapeutics to Present at the 8th Annual Dawson James Small Cap Growth Conference October 11, 2023 • 8:00 AM EDT
Kintara Therapeutics to Present at the LD Micro Main Event XVI Conference October 2, 2023 • 8:00 AM EDT